About

Liang Schweizer is the Founder, Board Chair and Chief Executive Officer of HiFiBiO Therapeutics. She has over 30 years of research and industry experience with numerous publications and global keynote presentations. She is the co-inventor of 12 immuno-modulatory therapeutic antibodies with over 50 patent publications. She also has contributed to 5 marketed drugs and over 30 clinical candidates. In recognition of her leadership, she has been awarded the EY Entrepreneur of the Year New England in 2024 and HiFiBiO Therapeutics recognized as a Fierce 15 Biotech in 2023.

Previously, Liang co-founded Harbour Biomed and served as its CSO, successfully transforming a technology platform company to an antibody drug discovery enterprise. Before launching her entrepreneurial career, Liang served as Head of Asian Cancer Research at Sanofi, advancing Sanofi’s Asia-Pacific oncology pipeline as well as contributing to global oncology programs from preclinical to clinical efforts. Before joining Sanofi, she was a director at Bristol-Myers Squibb Company.

Liang received a B.S. from the University of Science and Technology of China (USTC) and an M.S. in Microbial Engineering and Chemical Engineering from the University of Minnesota. She earned her Ph.D. in Molecular Biology from the University in Zurich. Her postdoctoral training was with Dr. Harold Varmus, a Nobel Laureate, at Memorial Sloan Kettering Cancer Center (MSKCC).